Phase I Study of TAS-102 Administered to Japanese Patients with Advanced Solid Tumors
Latest Information Update: 09 Nov 2018
Price :
$35 *
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 02 Jun 2016 New trial record